Clinical Trial Update: Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the effectiveness of Saccharomyces boulardii for gastrointestinal bacterial overgrowth in systemic sclerosis has been complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Intestinal Bacterial Overgrowth
• Systemic Sclerosis

Drugs mentioned

• Saccharomyces boulardii (Saccharomyces boulardii)

Snippet

Sponsor: Coordinación de Investigación en Salud, Mexico | Conditions: Systemic Sclerosis, Small Intestinal Bacterial Overgrowth | Phase 4 | Status: COMPLETED